McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

How do organic solar cells work on the inside? The answer lies in structures far too small to see—and difficult to access ...

Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phas ...

Creating artificial systems that mimic the functioning of cells is one of the goals of what is known as synthetic biology.

If scientists could shrink themselves to microscopic size and take a journey through the human body—like the submarine crew ...

Like tiny superheroes, small, naturally occurring segments of RNA can block multiple molecular paths that cancer cells use to grow and spread, a substantial advantage over ...

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...

Test analyses 74 genes and typically delivers results in 7 days upon sample receipt in the laboratory to support clinical ...

A 63-year-old Norwegian man shows no signs of HIV four years after receiving a stem cell transplant from his brother, making ...